Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Otsuka Dermatitis Candidate Looks Good At Phase III

Executive Summary

New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.

You may also be interested in...



Itching To Succeed: UNION Buys LEO Pharma’s PDE4 Inhibitor Series

Denmark-based UNION therapeutics has bought LEO Pharma’s PDE4 inhibitor compound series for use in developing treatments for psoriasis and atopic dermatitis.

Ono, PD-1 Discoverer Settle Long-Running Patent Dispute

Japanese firm and key discoverer of immuno-oncology protein reach settlement of patent-related dispute that includes formation of new academic research fund. 

Asia Deal Watch: CJ Group Continues Spree With Majority Stake Acquisition In Batavia Biosciences

Plus deals involving Zai Lab/Karuna, Zai Lab/Blueprint, Lotus/PharmaMar, Nippon Shinyaku/Dynacure, Alphamab/Ascletis, Aptose/Hanmi, Shanghai Pharmaceuticals/HUYABIO, KoBioLabs/SPH Sine, CURACLE/ Théa Open Innovation, Signet/XtalPi, Curi Bio/NEXEL, CANbridge/Scriptr and Ligand/CRDC.

Topics

Related Companies

UsernamePublicRestriction

Register

SC141956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel